ライフサイエンスコーパス: smoking cessation

1 ] control, cholesterol level management, and smoking cessation).

2 ressure control, cholesterol management, and smoking cessation).

3 n-hospital following ACS, is efficacious for smoking cessation.

4 tential methods and resources to assist with smoking cessation.

5 n reducing child TSE and increasing parental smoking cessation.

6 The primary endpoint was cigarette smoking cessation.

7 keletal muscle are most likely reversible by smoking cessation.

8 ddiction, smoking, cigarettes, nicotine, and smoking cessation.

9 four incentive programs or to usual care for smoking cessation.

10 esponse to nicotine patch or varenicline for smoking cessation.

11 cline is an effective pharmacotherapy to aid smoking cessation.

12 d by clinical guidelines recommending abrupt smoking cessation.

13 lution of epigenetic changes with time since smoking cessation.

14 g-related brain changes are reversible after smoking cessation.

15 [CI, 2.02 to 2.55]) were also effective for smoking cessation.

16 ly methylated, even more than 35 years after smoking cessation.

17 own regarding the underlying neurobiology of smoking cessation.

18 enicline's efficacy as a pharmacotherapy for smoking cessation.

19 rly and sustained antiretroviral therapy and smoking cessation.

20 ring pregnancy is considered ineffective for smoking cessation.

21 g negative effect modification by time since smoking cessation.

22 s inhaler) were most effective for achieving smoking cessation.

23 rettes per day, and a willingness to attempt smoking cessation.

24 ic obstructive pulmonary disease, even after smoking cessation.

25 o definitively establish their potential for smoking cessation.

26 risk, similar to the benefit associated with smoking cessation.

27 of the PFC and insula bilaterally can induce smoking cessation.

28 sk of EAC, although some evidence exists for smoking cessation.

29 nic cigarettes (e-cigarettes) may facilitate smoking cessation.

30 fect of motivational interviewing on nurses' smoking cessation.

31 ontributing to its ability to aid in tobacco smoking cessation.

32 vidence in support of the health benefits of smoking cessation.

33 determine the role of combination therapy in smoking cessation.

34 t of pretreatment upregulation of nAChRs and smoking cessation.

35 ks of smoking, and counseling patients about smoking cessation.

36 tic shared by pharmacologic agents promoting smoking cessation.

37 dies are needed to explore rTMS as an aid to smoking cessation.

38 s), diabetes risk was not elevated following smoking cessation.

39 or investigation of therapeutic potential in smoking cessation.

40 low-density lipoprotein >100 mg/dL, and (6) smoking cessation.

41 ) of alpha7 receptors, JNJ-39393406, may aid smoking cessation.

42 tion if nurses are to be effective agents of smoking cessation.

43 her be studied in a larger clinical trial of smoking cessation.

44 ation and airway wall remodeling, even after smoking cessation.

45 reduction, increasing physical activity, and smoking cessation.

46 altered methylation, with attenuation, after smoking cessation.

47 cial incentives increased long-term rates of smoking cessation.

48 the previous development of varenicline for smoking cessation.

49 hat, at many loci, persists many years after smoking cessation.

50 D prevention and tobacco cessation drugs for smoking cessation.

51 osylated hemoglobin (-0.92%; p < 0.001), and smoking cessation (20.2%; p = 0.002).

52 o implementing effective measures to promote smoking cessation, a crucial element of both the Framewo

53 ponse relationship exists and the time since smoking cessation affects methylation levels.

54 uggest an approach to help achieve sustained smoking cessation after a hospital stay.

55 Smoking cessation after acute myocardial infarction (AMI

56 We conclude that varenicline as a smoking cessation agent differs from nicotine through tr

57 ttempts to reduce the risk of IF may include smoking cessation, aggressive control of hyperglycemia,

58 pularity, but their safety and efficacy as a smoking cessation aid are not well understood.

59 e, popular antidepressant also marketed as a smoking cessation aid.

60 use of preventable diseases; thus, effective smoking cessation aids are crucial for reducing the prev

61 Despite efforts to produce suitable smoking cessation aids, addiction to nicotine continues

62 ts could serve as harm-reduction devices and smoking cessation aids.

63 chiatric and neurodegenerative disorders and smoking cessation aids.

64 re included informational resources and free smoking-cessation aids.

65 tinic acetylcholine receptor and is used for smoking cessation, almost doubles the chances of quittin

66 iation between e-cigarette use and cigarette smoking cessation among adult cigarette smokers, irrespe

67 pack-year of cigarette smoking by time since smoking cessation among former smokers.

68 re examined for association with prospective smoking cessation among smokers of European ancestry tre

69 Odds of smoking cessation among smokers using e-cigarettes compa

70 armacotherapy interventions improve rates of smoking cessation among the general adult population, al

71 ed programmes of screening, vaccination, and smoking cessation, among other prevention strategies.

72 Differential associations between smoking cessation and cancer risks by microsatellite ins

73 we examined associations between duration of smoking cessation and colorectal cancer risk according t

74 ated into most public health guidelines (eg, smoking cessation and control of bodyweight and blood pr

75 Smoking cessation and control of diastolic blood pressur

76 g cessation modified the association between smoking cessation and CVD events.

77 e has been approved in the United States for smoking cessation and cytisine is used in Eastern Europe

78 orporating both lifestyle changes, including smoking cessation and exercise, as well as optimal medic

79 ressed efficacy of electronic cigarettes for smoking cessation and found no benefit.

80 ote health initiatives in areas ranging from smoking cessation and healthy diet to organ transplantat

81 of reduced-nicotine cigarettes to facilitate smoking cessation and on policy regarding regulation of

82 Smoking cessation and participation in cardiac rehabilit

83 Reduction of DH may be achieved by smoking cessation and periodontal health improvements.

84 e findings emphasize the importance of early smoking cessation and preferably the avoidance of smokin

85 ing may be an effective way to increase male smoking cessation and reduce mother and newborn SHS expo

86 characterized by a negative mood state upon smoking cessation and relapse after periods of abstinenc

87 interventions increased adherence to ART and smoking cessation and should be considered for inclusion

88 he association between cigarette smoking and smoking cessation and the prevalence and incidence of to

89 the efficacy and safety of e-cigarettes for smoking cessation and to consider issues relevant to the

90 inform genetic therapeutic interventions for smoking cessation and tobacco-related diseases.

91 essure, low-density lipoprotein cholesterol, smoking cessation, and hemoglobin A1c.

92 Psilocybin is being tested for alcoholism, smoking cessation, and in patients with advanced cancer

93 ypical of never smokers within decades after smoking cessation, and sites remaining differentially me

94 l, lipid control, diabetic glycemic control, smoking cessation, and target body mass index by engagin

95 gnificantly increased within 3-9 years since smoking cessation, and the significant association persi

96 he dynamics of methylation changes following smoking cessation are driven by a differential and site-

97 Although diet, exercise, and smoking cessation are first steps for patients with a pr

98 Prevention and smoking cessation are still the main methods to reduce t

99 igarettes smoked and may be as effective for smoking cessation as the nicotine patch.

100 ettes per day, pack-years smoked, time since smoking cessation) as risk predictors.

101 ctiveness of TWH interventions for improving smoking cessation, as measured by self-reported 7-day ab

102 free medication resulted in higher rates of smoking cessation at 6 months compared with a standard r

103 Behavioral interventions increased smoking cessation at 6 months or more (physician advice

104 Smoking cessation at any age dramatically reduced death

105 Smoking cessation at least 1 year before major surgery a

106 se for the initialization and maintenance of smoking cessation because of their ability to block the

107 ic control and preventive measures including smoking cessation, blood pressure control, and lipid man

108 oking-related CMH usually resolves following smoking cessation but the longer its duration the greate

109 ffers an intriguing therapeutic approach for smoking cessation, but a reliably effective and immunolo

110 perceived stress may comprise a barrier for smoking cessation, but little is known about the associa

111 Smoking cessation by 10%-25% of HIV-infected smokers cou

112 Alcohol abstinence and smoking cessation can alter the progression of pancreati

113 Internet-based interventions for smoking cessation could help millions of people stop smo

114 They also indicate that smoking cessation could help reduce lung cancer risk for

115 Smoking cessation could potentially prevent more than 40

116 ACEI/ARB (OR: 2.6; 95% CI: 1.8 to 3.9), and smoking cessation counseling (OR: 4.4; 95% CI: 2.0 to 9.

117 RATIONALE: Smoking cessation counseling in conjunction with low-dos

118 Among current smokers with PAD, smoking cessation counseling or medication was used in 3

119 atients were less likely to receive statins, smoking cessation counseling, and defect-free care.

120 effectiveness of a medical (walking program, smoking cessation counseling, and medications) vs revasc

121 ho did not receive face-to-face or telephone smoking cessation counseling, large financial incentives

122 ceptor antagonists, use of beta-blocker, and smoking cessation counseling.

123 However, existing smoking cessation counselling and drugs are among the mo

124 -analysis of 9 trials that measured parental smoking cessation demonstrated no overall intervention e

125 his supports a net cardiovascular benefit of smoking cessation, despite subsequent weight gain.

126 otine has practical applications relating to smoking cessation devices and alternative nicotine produ

127 tes, and weight gain that occurred following smoking cessation did not modify this association.

128 Smoking cessation during nasal pneumococcal colonization

129 enuation was largely due to a higher rate of smoking cessation during the study period among men with

130 tcome expectancies support the importance of smoking cessation efforts in patients with orofacial pai

131 th screening, highlighting the importance of smoking cessation efforts in screening programs.

132 Lifestyle modifications such as smoking cessation, exercise, and weight control offer op

133 This issue provides a clinical overview of smoking cessation, focusing on health consequences of sm

134 ients to quit and 25% less likely to arrange smoking cessation follow-up.

135 cline, begun in-hospital, is efficacious for smoking cessation following ACS.

136 Most smoking cessation guidelines advise quitting abruptly.

137 therapy as an adjunct to diet, exercise, and smoking cessation has proven highly effective in reducin

138 ing at whether electronic cigarettes can aid smoking cessation have had inconsistent results.

139 ealth successes, including HIV treatment and smoking cessation, have contributed to declining prematu

140 Two trials targeting smoking cessation in adolescents failed to generate a po

141 erted effort should be made toward promoting smoking cessation in all patients scheduled for elective

142 Varenicline facilitates smoking cessation in clinical studies and reduced nicoti

143 nd telephone counseling, are efficacious for smoking cessation in CVD patients.

144 ce for a neurochemical target, which may aid smoking cessation in highly cue-reactive individuals.

145 ough which nicotinic compounds may be aiding smoking cessation in individuals experiencing withdrawal

146 dentify and overcome barriers to integrating smoking cessation in lung cancer screening settings.

147 SHS is an important factor associated with smoking cessation in lung cancer survivors of all stages

148 in the household) reduces the likelihood of smoking cessation in noncancer populations.

149 ead/neck cancers highlight the importance of smoking cessation in patients with cancer.

150 Infants born to women who used NRT for smoking cessation in pregnancy were more likely to have

151 explain hesitation among providers to pursue smoking cessation in SCZ.

152 Varenicline increased smoking cessation in smokers with stably treated current

153 nAChR PAM compound for possible efficacy in smoking cessation, in smokers with or without schizophre

154 actors associated with greater benefits from smoking cessation included younger age, higher initial C

155 The Smoking Cessation Intervention for Severe Mental Ill Hea

156 Mobile-phone-based smoking cessation intervention has been shown to increas

157 gn and test the efficacy over 12 months of a smoking cessation intervention targeting PLWHA.

158 2.6%], P = .01 for interaction term), and in smoking cessation interventions (12.4% vs 7.7%, differen

159 to consider in the design and development of smoking cessation interventions and tobacco regulation.

160 antipsychotic adverse effect monitoring, and smoking cessation interventions are needed from the earl

161 Although the efficacy and safety of smoking cessation interventions are well established, th

162 and safety of pharmacological and behavioral smoking cessation interventions in CVD patients via a me

163 g behaviours influence their engagement with smoking cessation interventions is needed.

164 l of nurses' engagement with the delivery of smoking cessation interventions requires attention if nu

165 g cancer screening setting of evidence-based smoking cessation interventions shown to be effective in

166 unding the integration and implementation of smoking cessation interventions with LDCT lung cancer sc

167 ized tools for use in conducting research on smoking cessation interventions within the LDCT lung can

168 The best approach for integrating effective smoking cessation interventions within this setting is u

169 d pressure control, cholesterol control, and smoking cessation interventions.

170 l illness and the effectiveness of available smoking cessation interventions.

171 Addressing smoking cessation is a critical component of comprehensi

172 Smoking cessation is an essential component of a high-qu

173 In type 2 diabetes, smoking cessation is associated with deterioration in gl

174 China, an immediate increase in the pace of smoking cessation is essential to avoid a rising burden

175 Although this benefit of smoking cessation is not extended to those with >/=32 pa

176 ssion of pancreatitis and reduce recurrence; smoking cessation is the most effective strategy to redu

177 Smoking cessation is the only way to quickly mitigate th

178 tly related to varenicline use, or caused by smoking cessation itself or reflects depression and suic

179 assess efficacy were biochemically verified smoking cessation, mean cigarettes smoked, stages of cha

180 nse telephone calls and their choice of free smoking cessation medication (any type approved by the U

181 provide a promising target in the search for smoking cessation medication with novel mechanisms of ac

182 Varenicline, an approved smoking cessation medication, showed clear efficacy in r

183 Smoking cessation medications are routinely used in heal

184 sed about the neuropsychiatric safety of the smoking cessation medications varenicline and bupropion.

185 st whether 4-year change in weight following smoking cessation modified the association between smoki

186 based programmes that promote weight loss or smoking cessation need to be more accessible for these p

187 uration of increased diabetes risk following smoking cessation needs further investigation.

188 In a randomized controlled trial of smoking cessation nested within the original prospective

189 ral modification, such as dietary changes or smoking cessation, not only reduces stroke risk, but als

190 Our results provide a new paradigm for how smoking cessation occurs and suggest how more effective

191 emiology data suggest a protective effect of smoking cessation on a DNA methylation-related carcinoge

192 own about the potential beneficial effect of smoking cessation on periodontal health.

193 stematic review is to evaluate the effect of smoking cessation on periodontitis progression and respo

194 for cataract development, but the effect of smoking cessation on the risk of cataract is uncertain.

195 stolic blood pressure, glycemic control, and smoking cessation, only 18% of the COURAGE diabetes subg

196 risks of smoking, and discuss with patients smoking cessation options.

197 ess to quit smoking, and most do not discuss smoking cessation options.

198 ake of targeted preventive services, such as smoking cessation or relevant immunizations; and the pos

199 icopathologic variables, and SHS with either smoking cessation or time to quitting.

200 y rated measures known to be associated with smoking cessation outcome.

201 ring early withdrawal may be associated with smoking cessation outcomes.

202 tween diabetic kidney disease and failure at smoking cessation (P=1.1x10(-4)).

203 Secondary outcomes of interest were parental smoking cessation, parental smoking reduction, and mater

204 controlled trials evaluating the efficacy of smoking cessation pharmacotherapies and behavioral thera

205 andomized to one of three 12-week open-label smoking cessation pharmacotherapy groups: (1) nicotine p

206 nAChRs may be a promising target for future smoking cessation pharmacotherapy.

207 us to optimise the selection and efficacy of smoking cessation pharmacotherapy.

208 udies were included if they reported nurses' smoking cessation practices in relation to their persona

209 Proportions of nurses' smoking status and smoking cessation practices were pooled across studies u

210 to have a negative impact in the delivery of smoking cessation practices.

211 nurses is associated with their professional smoking cessation practices.

212 nurses is associated with their professional smoking cessation practices.

213 An adjunct smoking cessation program has the potential to improve o

214 An adjunct smoking cessation program improving the quit rate by 22.

215 The effectiveness and safety of a smoking cessation programme designed particularly for pe

216 Smoking cessation programs and clinical advice should co

217 orporates systematic screening practice with smoking cessation programs and offers opportunities for

218 hould be a key consideration when developing smoking cessation programs for patients with lung cancer

219 and clinical trials evaluating the effect of smoking-cessation programs, alone or in combination with

220 and autonomic function may be restored after smoking cessation, providing further evidence in support

221 that validate a previously established v1.0 smoking cessation quit success genotype score and descri

222 The purpose of this study was to examine smoking cessation rates among smokers with AMI to determ

223 ompared with placebo significantly increased smoking cessation rates at the end of treatment, and als

224 with a clinically significant difference in smoking cessation rates compared with abrupt cessation.

225 arge financial incentives improved long-term smoking cessation rates in low-income smokers, in a gene

226 large financial incentives enhance long-term smoking cessation rates outside clinical or workplace se

227 status (slow/normal metabolism) may improve smoking cessation rates.

228 ing smokers with spirometry results improves smoking cessation rates.

229 sation occurs and suggest how more effective smoking cessation reagents can be designed.

230 Two-month smoking cessation reduced expression of 26 sphingolipids

231 Smoking cessation reduces the risks of cardiovascular di

232 line exerts a robust and favorable effect on smoking cessation relative to placebo and may have a fav

233 Smoking cessation results in withdrawal symptoms such as

234 Symptom prevalence following smoking cessation returned to levels seen among never-sm

235 was comparable, except for a higher rate of smoking cessation screening and intervention (adjusted r

236 Smoking cessation seems to decrease the risk of cataract

237 Based on the limited available evidence, smoking cessation seems to have a positive influence on

238 port and drugs, compared with a conventional smoking cessation service (ie, usual care).

239 slation (n=35), tobacco taxation (n=11), and smoking cessation services (n=3).

240 investigate optimal approaches for providing smoking cessation services in the dental setting.

241 oke but typically do not access conventional smoking cessation services, contributing to widening hea

242 ividuals assigned to usual care accessed NHS smoking cessation services.

243 moking but did cause a temporary doubling of smoking cessation shortly after randomisation during pre

244 % of MIs among HIV-infected individuals, and smoking cessation should be a primary focus in modern HI

245 on the benefits and harms of screening, and smoking cessation should be offered to all current smoke

246 tified in the postoperative period, although smoking cessation should be strongly encouraged given th

247 Smoking cessation should become a priority in HIV treatm

248 Smoking cessation significantly decreased the risk for c

249 ontrol group) or usual care plus the bespoke smoking cessation strategy (intervention group).

250 is a pilot randomised controlled trial of a smoking cessation strategy designed specifically for peo

251 The level of engagement with a bespoke smoking cessation strategy was higher than with a conven

252 Participants engaged well with the bespoke smoking cessation strategy, but no individuals assigned

253 net effect of radiotherapy on mortality, but smoking cessation substantially reduces radiotherapy ris

254 ice and an association between NRG3 SNPs and smoking cessation success was detected in a clinical tri

255 (a) we have identified genetic predictors of smoking cessation success, (b) genetic influences on qui

256 sis support the association of NRG3 SNPs and smoking cessation success.

257 hronic inflammation that persists even after smoking cessation, suggesting that a failure to resolve

258 genes remained elevated up to 30 years after smoking cessation, suggesting that the molecular consequ

259 The pooled effect of text messaging smoking cessation support on biochemically verified smok

260 se that smoke-free psychiatric units provide smoking cessation support on patient admission to the ho

261 show a higher risk in people 3-5 years after smoking cessation than in continuing smokers.

262 ed the evidence on interventions for tobacco smoking cessation that are relevant to primary care (beh

263 nternet-based intervention (StopAdvisor) for smoking cessation that was designed with particular atte

264 erved earlier, but more than 2 decades after smoking cessation, the risk of cataract extraction did n

265 After >15 years of smoking cessation, the risk of HF and death for most for

266 s entailed rewards of approximately $800 for smoking cessation; the others entailed refundable deposi

267 BAergic VTA neurons as molecular targets for smoking cessation therapeutics.

268 Smoking cessation therapies do not appear to raise the r

269 Improvements in smoking cessation therapies may be achieved by improving

270 there is historical and renewed concern that smoking cessation therapies may increase the risk of car

271 Current smoking cessation therapies offer limited success, as re

272 We aimed to examine whether the 3 licensed smoking cessation therapies-nicotine replacement therapy

273 the safety and efficacy of e-cigarettes as a smoking cessation therapy, available evidence showed no

274 evention efforts should continue to focus on smoking cessation, these prospective findings support th

275 ive to traditional cigarettes and a possible smoking cessation tool.

276 Cell phone-delivered smoking cessation treatment has a positive impact on abs

277 DP+ smokers and highlight novel targets for smoking cessation treatment in this population.

278 Among the 3 first-line smoking cessation treatments (nicotine replacement thera

279 thdrawal may inform the development of novel smoking cessation treatments and reduce the harm caused

280 izers may benefit from adjunctive behavioral smoking cessation treatments, such as cue exposure thera

281 varenicline and cytisine are widely used as smoking cessation treatments.

282 f nicotine replacement therapy (NRT) use and smoking cessation using data from the Ontario Tobacco Su

283 of smoking-induced epigenetic changes after smoking cessation, using genome-wide methylation profile

284 Whether this health benefit of smoking cessation varies by amount and duration of prior

285 cessation support on biochemically verified smoking cessation was (RR 2.16 [95% CI 1.77-2.62]).

286 In this community-based cohort, smoking cessation was associated with a lower risk of CV

287 Smoking cessation was consistently associated with a red

288 Smoking cessation was highest among individuals who rece

289 15 cigarettes or less per day, the effect of smoking cessation was observed earlier, but more than 2

290 The overall rate of smoking cessation was similar between participants in th

291 mood and behavior independent of smoking and smoking cessation, we assessed the effects of vareniclin

292 To better understand smoking cessation, we examined the actions of vareniclin

293 to receive either booklets plus access to a smoking cessation website (control group, n = 404), or t

294 Higher rates of smoking cessation were associated with NRT (17.6%) and b

295 Changes in lipid expression after 2-month smoking cessation were investigated in smokers with and

296 The benefits of smoking cessation were underestimated in previous studie

297 counseling (exercise or diet counseling and smoking cessation) were evaluated.

298 In addition, smoking cessation, whether before or after onset of the

299 Prospective evidence of the associations of smoking cessation with chronic obstructive pulmonary dis

300 viours (active smoking, passive smoking, and smoking cessation) with risk of type 2 diabetes.